Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

Market Cap	8.95B +12.8%
Revenue (ttm)	1.68B +9.2%
Net Income	393.72M +0.4%
EPS	0.96 -2.8%
Shares Out	403.41M
PE Ratio	23.04
Forward PE	16.32
Dividend	0.34 (1.50%)
Ex-Dividend Date	Jun 20, 2025

Volume	4,234,900
Average Volume	6,653,799
Open	22.62
Previous Close	22.62
Day's Range	22.10 - 22.65
52-Week Range	20.18 - 35.58
Beta	-0.30
RSI	30.82
Earnings Date	Apr 17, 2026

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 1,784
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605116

Financial Performance

In 2025, Aurisco Pharmaceutical's revenue was 1.70 billion, an increase of 15.03% compared to the previous year's 1.48 billion. Earnings were 449.21 million, an increase of 26.61%.